Search - tctmd.com

Displaying 41 - 60 of 386

Sort: Relevancy | Date

Genetic Risk Score for Endothelial Cell Dysfunction Identifies Patients at Risk

News Daily News

Genetic Risk Score for Endothelial Cell Dysfunction May Help Hone ASCVD Care

Michael O'Riordan

February 27, 2025

GLP-1 Drugs in Diabetes Don’t Raise Suicidality Risk, New Data Confirm

News Daily News

GLP-1 Drugs in Diabetes Don’t Raise Suicidality Risk, New Data Confirm

February 26, 2025

Aortic Stenosis Slowed by SGLT2 Inhibitors in Observational Study

News Daily News

Aortic Stenosis Slowed by SGLT2 Inhibitors in Observational Study

Yael L. Maxwell

February 20, 2025

Elderly ASCVD Patients Benefit From Aggressive LDL-Lowering With Evolocumab

News Daily News

Elderly ASCVD Patients Benefit From Aggressive LDL-Lowering With Evolocumab

Michael O'Riordan

February 05, 2025

CVD Risks Vary by Type of Menopausal Hormone Replacement Therapy

News Daily News

CVD Risks Vary by Type of Menopausal Hormone Replacement Therapy

December 04, 2024

Rivaroxaban Doesn’t Cut Cognitive Decline, Stroke, or TIA in Younger AF Patients

News Conference News AHA 2024

Rivaroxaban Doesn’t Cut Cognitive Decline, Stroke, or TIA in Younger AF Patients

November 16, 2024

SUMMIT: Tirzepatide ‘Huge Win’ for HFpEF Patients With Obesity

News Conference News AHA 2024

SUMMIT: Tirzepatide a ‘Huge Win’ for HFpEF Patients With Obesity

Michael O'Riordan

November 16, 2024

Study Validates Accuracy of PREVENT for CVD Mortality Risk Prediction

News Daily News

Study Validates Accuracy of PREVENT for CVD Mortality Risk Prediction

October 15, 2024

SENIOR-RITA Offers Rare Insights Into Best Care for Older NSTEMI Patients

News Conference News ESC 2024

SENIOR-RITA Offers Rare Insights Into Best Care for Older NSTEMI Patients

Michael O'Riordan

September 02, 2024

Getting to Cholesterol Goal Early After MI Lowers Risk of Recurrent Events

News Conference News ESC 2024

Getting to Cholesterol Goal Early After MI Lowers Risk of Recurrent Events

Michael O'Riordan

September 01, 2024

Edoxaban Monotherapy Wins for AF and Stable Coronary Disease: EPIC-CAD

News Conference News ESC 2024

Edoxaban Monotherapy Wins for AF and Stable Coronary Disease: EPIC-CAD

September 01, 2024

Three Common Biomarkers Closely Tied to Women’s 30-Year Risk of CV Events

News Conference News ESC 2024

Three Common Biomarkers Closely Tied to Women’s 30-Year Risk of CV Events

August 31, 2024

New BedMed Data Confirm Antihypertensives Can Be Taken Any Time of Day

News Conference News ESC 2024

New BedMed Data Confirm Antihypertensives Can Be Taken Any Time of Day

Yael L. Maxwell

August 31, 2024

Good News for CV Recovery After COVID-19 Vaccine Myocarditis

News Daily News

Good News for CV Recovery After COVID-19 Vaccine Myocarditis

Yael L. Maxwell

August 29, 2024

New Data Reassure on Rivaroxaban’s Role in Frail PAD Patients

News Daily News

New Data Reassure on Rivaroxaban’s Role in Frail PAD Patients

August 19, 2024

Both SGLT2 and GLP-1 Drugs Help Heart and Kidneys in Type 2 Diabetes

News Daily News

Both SGLT2 and GLP-1 Drugs Help Heart and Kidneys in Type 2 Diabetes

Michael O'Riordan

August 19, 2024

Semaglutide May Ease Tobacco Use, Study Suggests

News Daily News

Semaglutide May Ease Tobacco Use, Study Suggests

August 01, 2024

SUMMIT Meets Primary Endpoint for Safety, Efficacy of Tirzepatide: Topline Results

News Daily News

SUMMIT Meets Primary Endpoint for Safety, Efficacy of Tirzepatide: Topline Results

Yael L. Maxwell

August 01, 2024

Coronary Calcium Scoring May Help Get Semaglutide to Highest-Risk Patients

News Conference News SCCT 2024

Coronary Calcium Scoring May Help Get Semaglutide to Highest-Risk Patients

July 22, 2024

No Uptick in Suicidal Thinking With GLP-1 Drugs: Medicare Data

News Daily News

No Uptick in Suicidal Thinking With GLP-1 Drugs: Medicare Data

Yael L. Maxwell

July 15, 2024

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.